BELLUS Health Announces Positive Results from its Phase 1 Bioavailability Equivalence Study Evaluating Once-Daily Extended-Release Formulation of Camlipixant in Comparison to Twice-Daily Immediate Release Formulation

Once-daily Extended-Release formulation demonstrated equivalent bioavailability to twice-daily Immediate Release formulation


Extended-Release formulation was well tolerated, with the safety profile... | April 5, 2023

Related Keywords

United Kingdom ,United States ,Canada ,Canadian ,Roberto Bellini ,Health Inc ,Nasdaq ,European Union ,Exchange Commission ,Immediate Release ,Chief Executive Officer ,Securities Litigation Reform Act ,Annual Information Form ,United States Securities ,Annual Report ,Bellus Health Inc Stock Exchange ,News ,Information ,Press Release ,Formulation ,Remonstrated ,Equivalent ,Bioavailability ,O ,Immediate ,Release ,Gas ,Fell ,Ith ,The ,Afety Blu Ca07987c2040 ,